EDITORIAL COMMENTARY
Impact of hepatitis C virus infection control on preventing the postoperative recurrence of intrahepatic cholangiocarcinoma
This article relates to:
-
Favorable impact of hepatitis C virus infection control on recurrence after surgical resection for intrahepatic cholangiocarcinoma
- Masahiko Kinoshita,
- Hisashi Kosaka,
- Masaki Kaibori,
- Masaki Ueno,
- Satoshi Yasuda,
- Koji Komeda,
- Yusuke Yamamoto,
- Masaji Tani,
- Tsukasa Aihara,
- Hiroji Shinkawa,
- Shinya Hayami,
- Yasuko Matsuo,
- Nao Kawaguchi,
- Ryo Morimura,
- Haruki Mori,
- Takayoshi Nakajima,
- Shoji Kubo,
- Takeaki Ishizawa,
- Volume 55Issue 5Hepatology Research
- pages: 707-717
- First Published online: December 14, 2024
Takashi Kokudo,
Norihiro Kokudo,
Corresponding Author
Takashi Kokudo
National Center for Global Health and Medicine, Tokyo, Japan
Correspondence
Takashi Kokudo, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan.
Email: [email protected]
Search for more papers by this authorNorihiro Kokudo
National Center for Global Health and Medicine, Tokyo, Japan
Search for more papers by this authorTakashi Kokudo,
Norihiro Kokudo,
Corresponding Author
Takashi Kokudo
National Center for Global Health and Medicine, Tokyo, Japan
Correspondence
Takashi Kokudo, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan.
Email: [email protected]
Search for more papers by this authorNorihiro Kokudo
National Center for Global Health and Medicine, Tokyo, Japan
Search for more papers by this authorFirst published: 18 March 2025
No abstract is available for this article.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflicts of interest.
REFERENCES
- 1Chuang SC, La Vecchia C, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett. 2009; 286(1): 9–14. https://doi.org/10.1016/j.canlet.2008.10.040
- 2Abe H, Okamura Y, Yoshida N, Mitsuka Y, Aramaki O, Moriguchi M, et al. Impact of sustained virological response on long-term outcomes after curative resection in patients with hepatitis C virus-related hepatocellular carcinoma in the Era of direct-acting antiviral therapy. Ann Surg Oncol. 2024; 32(2): 1093–1104. in press. https://doi.org/10.1245/s10434-024-16453-9
- 3Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavò MR, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 2019; 71(2): 265–273. https://doi.org/10.1016/j.jhep.2019.03.027
- 4Navas MC, Glaser S, Dhruv H, Celinski S, Alpini G, Meng F. Hepatitis C virus infection and cholangiocarcinoma: an Insight into epidemiologic evidences and hypothetical mechanisms of oncogenesis. Am J Pathol. 2019; 189(6): 1122–1132. https://doi.org/10.1016/j.ajpath.2019.01.018
- 5El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology. 2009; 49(1): 116–123. https://doi.org/10.1002/hep.22606
- 6Cheo FY, Chan KS, Shelat VG. Outcomes of liver resection in hepatitis C virus-related intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. World J Virol. 2024; 13(1):88946. https://doi.org/10.5501/wjv.v13.i1.88946
- 7Wu T-T, Levy M, Correa AM, Rosen CB, Abraham SC. Biliary intraepithelial neoplasia in patients without chronic biliary disease: analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic liver. diseases Cancer. 2009; 115(19): 4564–4575. https://doi.org/10.1002/cncr.24471
10.1002/cncr.24471 Google Scholar
- 8Kaibori M, Yoshii K, Kashiwabara K, Kokudo T, Hasegawa K, Izumi N, et al. Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: report of a Japanese nationwide survey. Hepatol Res. 2021; 51(8): 890–901. https://doi.org/10.1111/hepr.13676
- 9Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013; 368(20): 1907–1917. https://doi.org/10.1056/nejmra1213651
- 10Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology. 2013; 58(1): 150–157. https://doi.org/10.1002/hep.26300
- 11Di Stasio D, Guida A, Romano A, Petruzzi M, Marrone A, Fiori F, et al. Hepatitis C virus (HCV) infection: pathogenesis, oral manifestations, and the role of direct-acting antiviral therapy: a narrative review. J Clin Med. 2024; 13(14):4012. https://doi.org/10.3390/jcm13144012
- 12Tanaka S, Shinkawa H, Tamori A, Takemura S, Takahashi S, Amano R, et al. Surgical outcomes for hepatocellular carcinoma detected after hepatitis C virus eradiation by direct-acting antivirals. J Surg Oncol. 2020; 122(8): 1543–1552. https://doi.org/10.1002/jso.26184
- 13Torre P, Festa M, Sarcina T, Masarone M, Persico M. Elimination of HCV infection: recent epidemiological findings, barriers, and strategies for the coming years. Viruses. 2024; 16(11):1792. https://doi.org/10.3390/v16111792
- 14Kinoshita M, Kosaka H, Kaibori M, Ueno M, Yasuda S, Komeda K, et al. Favorable impact of hepatitis C virus infection control on recurrence after surgical resection for intrahepatic cholangiocarcinoma. Hepatol Res. 2024. in press.
- 15Cheo FY, Chan KS, Shelat VG. Outcomes of liver resection in hepatitis C virus-related intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. World J Virol. 2024; 13(1):88946. https://doi.org/10.5501/wjv.v13.i1.88946
- 16Alvaro D, Gores GJ, Walicki J, Hassan C, Sapisochin G, Komuta M, et al. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023; 79(1): 181–208. https://doi.org/10.1016/j.jhep.2023.03.010
- 17Kamal A, Metawea M, Omar H, Ghallab M, Kassem A, Naguib H. Hepatitis C virus-related one-year hepatocellular carcinoma recurrence after directly acting antivirals: a randomized controlled trial. J Gastrointest Cancer. 2024; 55(2): 913–923. https://doi.org/10.1007/s12029-024-01035-5
